Wong, Florence; Watson, Hugh; Gerbes, Alexander; Vilstrup, Hendrik; Badalamenti, Salvatore; Bernardi, Mauro; Ginès, Pere
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity.
In: Gut, Vol. 61, No. 1: pp. 108-16
Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in short-term phase II studies. The aim of this study was to evaluate the efficacy and safety of satavaptan in three different populations of patients with cirrhosis and ascites.